280 related articles for article (PubMed ID: 27864835)
1. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
2. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
3. Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Andrici J; Goeppert B; Sioson L; Clarkson A; Renner M; Stenzinger A; Tayao M; Watson N; Farzin M; Toon CW; Smith RC; Mittal A; Samra JS; Hugh TJ; Chou A; Lawlor RT; Weichert W; Schirmacher P; Sperandio N; Ruzzenente A; Scarpa A; Gill AJ
Medicine (Baltimore); 2016 Jan; 95(2):e2491. PubMed ID: 26765459
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
[TBL] [Abstract][Full Text] [Related]
5. Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Am J Surg Pathol; 2016 Aug; 40(8):1021-30. PubMed ID: 27259014
[TBL] [Abstract][Full Text] [Related]
6. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
7. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
8. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
9. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.
Tanaka M; Shibahara J; Ishikawa S; Ushiku T; Morikawa T; Shinozaki-Ushiku A; Hayashi A; Misumi K; Tanaka A; Katoh H; Sakuma K; Kokudo T; Inagaki Y; Arita J; Sakamoto Y; Hasegawa K; Fukayama M
Virchows Arch; 2019 Jan; 474(1):39-46. PubMed ID: 30349952
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
[TBL] [Abstract][Full Text] [Related]
11. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
12. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C
Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198
[TBL] [Abstract][Full Text] [Related]
14. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
[TBL] [Abstract][Full Text] [Related]
15. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma.
Li Q; Wang JM; Liu C; Xiao BL; Lu JX; Zou SQ
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):70-5. PubMed ID: 18234642
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma.
Yamada M; Yamamoto Y; Sugiura T; Kakuda Y; Ashida R; Tamura S; Okamura Y; Ito T; Ohgi K; Nakanuma Y; Uesaka K
Anticancer Res; 2019 Apr; 39(4):2121-2127. PubMed ID: 30952758
[TBL] [Abstract][Full Text] [Related]
17. Loss of expression of BAP1 predicts longer survival in mesothelioma.
Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ
Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359
[TBL] [Abstract][Full Text] [Related]
18. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
[TBL] [Abstract][Full Text] [Related]
19. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
[TBL] [Abstract][Full Text] [Related]
20. PBRM1 loss is a late event during the development of cholangiocarcinoma.
Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD
Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
